allon therapeutics inc third quarter report september 30 2006q3 neuroprotection one step n corporate profile is a canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as alzheimer s disease mild cognitive impairment stroke and traumatic brain injury compounds come from two technology platforms derived neuroprotective proteins are formed naturally in the these have demonstrated broad efficacy numerous pre clinical models of diseases expects to products phase ii human trials by end 2006 al 108 an eight amino acid peptide formulated intranasally for 2005 completed ia trial confirming safety tolerability healthy adults during began ib dosing subsequent plans begin iia year 208 intravenously resulting coronary artery bypass graft surgery i evaluating
